Is anyone subscribed?

His take on MNKD has been quite bearish in the past:

http://www.thestreet.com/story/11888089/1/biotech-stock-mailbag-mannkind-ariad-oncolytics-biotech.html

and Adam F. from the street referenced he put out a new article today on Afrezza.

I would quite interested if he has anything new to add, or the same old focus on Afrezzas use in the Type 1 market.